The Cost Problem Your Patients Are Facing

If you prescribe Qvar RediHaler (Beclomethasone Dipropionate), chances are you've had patients come back to tell you they couldn't afford it — or worse, they never filled the prescription at all. Medication abandonment due to cost is a persistent problem in respiratory care, and brand-name inhalers like Qvar sit squarely in the crosshairs.

This guide is designed to help you, as a prescribing provider, understand the current pricing landscape for Qvar and equip you with actionable strategies to help your patients access their medication without financial hardship.

What Patients Are Paying for Qvar

Cash Price

Without insurance, Qvar RediHaler costs approximately $306 to $414 per inhaler (10.6g canister, 120 inhalations). For patients using the 80 mcg strength twice daily, one inhaler typically lasts about one month — making this a recurring $300+ monthly expense for uninsured patients.

With Commercial Insurance

Most commercial plans cover Qvar as a Tier 3 (preferred brand) medication. However, patient copays vary widely:

• Plans with traditional copay structures: $30 to $75 per fill
• Plans with coinsurance: patients may owe 20% to 40% of the list price until they meet their deductible
• High-deductible health plans (HDHPs): patients may pay the full cash price until the deductible is met

Some plans require prior authorization or step therapy (trial of another ICS first). If your patient has been through step therapy and still needs Qvar specifically, documenting this clearly can expedite approvals.

Medicare Part D

Qvar is typically covered under Medicare Part D. However, during the coverage gap ("donut hole"), costs can increase substantially. The Inflation Reduction Act has been reducing out-of-pocket maximums, but many Medicare patients still face significant costs for brand-name inhalers.

Uninsured and Underinsured Patients

This is where the problem is most acute. Without any coverage or assistance, patients are looking at over $3,600 per year for a single maintenance inhaler. Predictably, this is where you see the highest rates of non-adherence and prescription abandonment.

Manufacturer Savings Programs

Teva Savings Card

Teva offers a copay assistance card for commercially insured patients:

• Eligible patients may pay as little as $15 per fill
• Teva covers up to $25 of the copay
• Maximum savings of $40 per fill
• Up to 25 fills per year
• Available through qvar.com

Limitations: Not available for government-insured patients (Medicare, Medicaid, Tricare, VA). The savings cap of $40 per fill may not be sufficient for patients with high coinsurance or deductible-phase costs.

Teva Cares Foundation (Patient Assistance Program)

For uninsured or underinsured patients who meet income requirements:

• Free medication provided directly to eligible patients
• Application available through qvar.com or tevausa.com
• Income eligibility requirements apply (typically 200-400% of federal poverty level, though specific thresholds vary)

This is the most impactful option for your uninsured patients. Consider keeping applications in your office or having staff assist patients with the enrollment process.

Coupon and Discount Cards

For patients who don't qualify for manufacturer programs — particularly those with government insurance or income above PAP thresholds — third-party discount cards can provide meaningful savings:

Key Discount Platforms

• GoodRx — widely recognized, shows prices at multiple pharmacies with downloadable coupons
• SingleCare — free discount card accepted at most major pharmacy chains
• RxSaver — compares prices across pharmacies with printable or digital coupons
• Optum Perks — discounts through UnitedHealth Group's platform
• BuzzRx — free card with no registration required

These cards don't apply to insurance copays — they replace insurance entirely for that transaction, providing a negotiated cash price. For some patients, especially those in the deductible phase of a high-deductible plan, the discount card price may actually be lower than their insurance copay.

Clinical note: Advise patients that using a discount card instead of insurance means the purchase won't count toward their deductible. This is a tradeoff worth discussing.

Generic Alternatives

As of 2026, no generic Qvar RediHaler is available. Patents are expected to expire around May 2031. However, there are therapeutic alternatives in the inhaled corticosteroid class that offer lower-cost options:

Therapeutic Alternatives

• Fluticasone Propionate HFA (generic Flovent) — the most widely available generic ICS in MDI form. Significantly lower cost. Note: metabolized through CYP3A4, so higher interaction risk with protease inhibitors and azole antifungals.
• Budesonide (generic Pulmicort) — available as a generic nebulizer solution. The Flexhaler remains brand-only. Good option for pediatric patients who use a nebulizer.
• Ciclesonide (Alvesco) — brand-only, but once-daily dosing may improve adherence. Prodrug design may reduce oral thrush. Cost may be comparable to Qvar.
• Mometasone (Asmanex) — available in DPI and MDI forms. Some generics available depending on formulation.

When Switching Makes Sense

Consider a therapeutic switch when:

• Cost is a barrier to adherence and no assistance programs are available
• The patient has been on Qvar for stabilization and could transition to a lower-cost ICS
• Insurance formulary changes have made Qvar prohibitively expensive
• A generic ICS is clinically appropriate for the patient's severity level

When switching, document the clinical rationale and inform the patient that different inhalers may have different techniques, onset profiles, and side effect profiles.

When Switching Doesn't Make Sense

• Patient is well-controlled on Qvar with good inhaler technique
• Patient has CYP3A4 interaction concerns (HIV patients on protease inhibitors) — Qvar's esterase-based metabolism is advantageous here
• Patient has had poor outcomes or intolerance with other ICS options
• Patient specifically needs the breath-actuated design for proper drug delivery

Building Cost Conversations Into Your Workflow

Addressing medication cost shouldn't be an afterthought. Here are practical ways to integrate cost awareness into your prescribing workflow:

At the Point of Prescribing

• Ask about insurance and cost concerns — A simple "Do you have any concerns about the cost of this medication?" opens the door without assumption.
• Check formulary status — If your EHR integrates with insurance formularies, verify that Qvar is covered before prescribing. If it requires PA, consider whether a formulary-preferred alternative would be equally effective.
• Provide savings information proactively — Hand patients the Teva Savings Card information at the time of prescribing, not after they've abandoned the prescription.

At Follow-Up Visits

• Ask about adherence and cost — "Have you been able to fill and use your Qvar regularly?" Non-adherence is often cost-driven.
• Reassess cost-effectiveness — If a patient is stable, consider whether a lower-cost ICS could maintain control.
• Update assistance program enrollment — Income and insurance situations change. Re-screen patients annually for program eligibility.

Staff and Workflow Integration

• Train medical assistants or pharmacy liaisons to screen for savings program eligibility
• Keep Teva Savings Card materials and PAP applications stocked in exam rooms
• Bookmark Medfinder for Providers for quick access to pharmacy stock and pricing information
• Create a simple reference sheet listing ICS alternatives with relative cost tiers

Helping Patients Find Qvar in Stock

Cost isn't the only barrier — availability can be a challenge too. When patients report difficulty finding Qvar:

• Direct them to Medfinder to check pharmacy stock in their area
• Consider sending prescriptions to pharmacies more likely to carry brand-name inhalers (larger chain locations, specialty pharmacies)
• Discuss mail-order pharmacy options, which may offer more consistent supply
• For more strategies, see our provider's guide to helping patients find Qvar in stock

Final Thoughts

Medication cost is one of the most modifiable barriers to asthma control. As prescribers, we have more leverage than we sometimes realize — through savings program enrollment, strategic formulary navigation, therapeutic substitution when appropriate, and simply asking patients about cost.

Qvar RediHaler is an effective, well-tolerated maintenance inhaler. When patients can afford it and access it consistently, outcomes improve. The tools exist to make that possible for most patients — the key is integrating them into routine clinical workflow rather than waiting for the patient to hit a wall.

For patient-facing resources on Qvar savings, refer patients to our guide on coupons, discounts, and patient assistance for Qvar.